Role of Anti-Androgens in the Management of Polycystic Ovary Syndrome (PCOS)
Fuente:
Zenodo
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Recurso digital |
| Pubblicazione: |
Zenodo
2025
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866901942516580352 |
|---|---|
| author | J. S. Venkatesh, Dr. Santosh Uttangi, Abhila B, Abhishek S*, Aksa Rajan, K Parvati |
| author_facet | J. S. Venkatesh, Dr. Santosh Uttangi, Abhila B, Abhishek S*, Aksa Rajan, K Parvati |
| contents | <p><span lang="EN-US">Polycystic ovary syndrome (PCOS) is a common hormonal disorder in women of reproductive age. It is marked by high levels of androgens, problems with ovulation, and the presence of many cysts in the ovaries. Anti-androgens (AAs), such as spironolactone, flutamide, finasteride, and cyproterone acetate (when taken with ethinyl estradiol), are often used to manage symptoms caused by excessive androgens, mainly hirsutism and acne. They may also help with other metabolic or adnexal issues. This review covers the mechanisms behind these treatments, their clinical effectiveness, evidence comparing them, safety concerns (especially liver damage and risks to a developing fetus), recommendations from guidelines, and practical prescribing tips. Key evidence supports the use of anti-androgens, typically with effective contraception, for managing symptoms of high androgen levels when pregnancy is not intended. However, there are still uncertainties regarding long-term safety, effects on metabolism, and direct comparisons among different agents. Future research on anti-androgens in PCOS aims to improve metabolic health, lower long-term risks related to heart and metabolism, and increase ovulation rates in women with high androgen levels. Studies are looking into combination treatments for severe hair loss, safe use in adolescents, personalized approaches based on genetic profiles, and new topical forms to lower systemic risks. Long-term management for stubborn hirsutism also remains a major focus.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17803662 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Role of Anti-Androgens in the Management of Polycystic Ovary Syndrome (PCOS) J. S. Venkatesh, Dr. Santosh Uttangi, Abhila B, Abhishek S*, Aksa Rajan, K Parvati PCOS, anti-androgens, spironolactone, cyproterone acetate, hirsutism, hormonal therapy <p><span lang="EN-US">Polycystic ovary syndrome (PCOS) is a common hormonal disorder in women of reproductive age. It is marked by high levels of androgens, problems with ovulation, and the presence of many cysts in the ovaries. Anti-androgens (AAs), such as spironolactone, flutamide, finasteride, and cyproterone acetate (when taken with ethinyl estradiol), are often used to manage symptoms caused by excessive androgens, mainly hirsutism and acne. They may also help with other metabolic or adnexal issues. This review covers the mechanisms behind these treatments, their clinical effectiveness, evidence comparing them, safety concerns (especially liver damage and risks to a developing fetus), recommendations from guidelines, and practical prescribing tips. Key evidence supports the use of anti-androgens, typically with effective contraception, for managing symptoms of high androgen levels when pregnancy is not intended. However, there are still uncertainties regarding long-term safety, effects on metabolism, and direct comparisons among different agents. Future research on anti-androgens in PCOS aims to improve metabolic health, lower long-term risks related to heart and metabolism, and increase ovulation rates in women with high androgen levels. Studies are looking into combination treatments for severe hair loss, safe use in adolescents, personalized approaches based on genetic profiles, and new topical forms to lower systemic risks. Long-term management for stubborn hirsutism also remains a major focus.</span></p> |
| title | Role of Anti-Androgens in the Management of Polycystic Ovary Syndrome (PCOS) |
| topic | PCOS, anti-androgens, spironolactone, cyproterone acetate, hirsutism, hormonal therapy |
| url | https://doi.org/10.5281/zenodo.17803662 |